Mitoxantrone during robotic thyroid cancer surgery
Part of Cancer, Hormones & metabolism clinical trials.
This trial tests a new way to use a medication called mitoxantrone during robotic thyroid cancer surgery. The goal is to see if it helps protect the parathyroid glands (tiny glands near your thyroid) and improve surgery outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- Your thyroid cancer tumor is smaller than 4 cm and confirmed by a biopsy or ultrasound.
- You are healthy enough for surgery based on routine pre-operation tests.
- You are able to have your thyroid lobe or the whole thyroid removed, along with nearby lymph nodes.
- You are willing to join the study, sign a consent form, and follow up as needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether the timing of a carbon nanoparticle injection during thyroid cancer surgery improves outcomes. It may help patients who need their whole thyroid removed and have cancer in both lobes or spread to lymph nodes.
This study looks at whether certain cancer “targeted therapy” medicines can make radioactive iodine (RAI) therapy work better for thyroid cancer that has spread to the lungs. It also involves taking special whole-body scans to measure how much radioactive iodine gets taken up by the cancer.
This trial tests whether giving targeted drugs before surgery can shrink advanced thyroid cancers that are hard to remove. It uses genetic test results to match you to a specific treatment arm, aiming to make surgery safer and more successful.
This study tests whether giving treatment before surgery (neoadjuvant therapy) helps people with locally advanced thyroid cancer. It aims to shrink the tumor so surgery can be more successful.
This study compares a robotic surgery method using small incisions under the armpit with standard open surgery for papillary thyroid cancer that has spread to lymph nodes on one side of the neck. It aims to see which approach is better for removing cancer and recovery.
This trial tests a combination of two drugs, anlotinib (a targeted therapy) and benmelstobart (an immunotherapy), for people with differentiated thyroid cancer that has spread or cannot be removed. It may be an option if your cancer did not respond to or got worse after first treatment.
Hear when a new Papillary Thyroid Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.